Hikal Sustainability Profile
Hikal Limited, a prominent player in the pharmaceutical and agrochemical sectors, is headquartered in India. Established in 1988, the company has made significant strides in providing high-quality active pharmaceutical ingredients (APIs) and intermediates, alongside a diverse range of agrochemical products. With a strong operational presence across India and international markets, Hikal has positioned itself as a trusted partner for global pharmaceutical and agricultural companies. Hikal's core offerings include custom synthesis, contract manufacturing, and a robust portfolio of APIs that cater to various therapeutic areas. The company is recognised for its commitment to quality and innovation, which has earned it several industry accolades. As a leader in its field, Hikal continues to drive advancements in sustainable practices and technology, solidifying its reputation as a key contributor to the global healthcare and agriculture landscape.
DitchCarbon Score
How does Hikal's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikal's score of 32 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikal's reported carbon emissions
In 2024, Hikal Limited reported total carbon emissions of approximately 88,218,720 kg CO2e, comprising about 21,410,710 kg CO2e from Scope 1 and about 67,287,010 kg CO2e from Scope 2. This represents a slight decrease in emissions compared to 2023, where total emissions were approximately 94,710,540 kg CO2e, with Scope 1 emissions at about 26,793,240 kg CO2e and Scope 2 emissions at about 67,737,300 kg CO2e. Hikal has set an ambitious target to achieve a 30% reduction in both Scope 1 and Scope 2 emissions by the fiscal year 2027-28, using 2022-23 levels as a baseline. This commitment reflects the company's proactive approach to decarbonisation within the pharmaceuticals, biotechnology, and life sciences sector. The company has not disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from its operations. Hikal's emissions intensity metrics show a trend towards improved efficiency, with a reported intensity of 0.11372 kg CO2e per rupee of turnover in 2024, down from 0.10692 kg CO2e in 2023. Hikal's climate commitments are aligned with industry standards, demonstrating a clear pathway towards reducing its carbon footprint while maintaining operational growth.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 57,457,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Hikal's Industry?
How Carbon Intensive is Hikal's Location?
Hikal's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hikal has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
